Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2020

View Archived Issues

Metacrine reports phase I data on FXR agonist MET-642

Interim analysis update on remestemcel-L study in COVID-19 ARDS

Phase II study of BN-Brachyury in chordoma shows signs of clinical activity

Olinvacimab plus pembrolizumab shows clinical benefit in phase Ib study in mTNBC

DZD-4205 demonstrates efficacy in phase I/II JACKPOT8 study in PTCL

Discovery of new PDIA1 inhibitor with antitumor activity in models of multiple myeloma

Chiesi Farmaceutici divulges new P2X3 receptor antagonists

Sage Therapeutics synthesizes CYP46A1 inhibitors

Kallyope identifies new FFAR1 agonists

Korea Pharma describes JAK1 inhibitors

University of California, Oakland patents modified ZIVK-based products for cancer

Preliminary phase I/II data for ZN-c5 monotherapy in ER-positive/HER2-negative breast cancer

Triumeq shown to slow down progression of MND in mice

Tumors, metastases activate mTOR in different ways

Soricimed to explore utility of SOR-C13 for COVID-19

FDA approves Orgovyx for advanced prostate cancer

FDA issues EUA for Moderna's mRNA-1273 for COVID-19

Phase III studies of faricimab in DME meet primary endpoint

FDA issues complete response letter for inclisiran

Qu Biologics to evaluate potential of QBKPN to prevent and treat SARS-CoV-2 infection

XEN-496 shows comparable PK data to that of retigabine

Nanoform announces first human dosing with nanoformed drug

European Commission approves Palforzia to treat peanut allergy

LACEWING study of Xospata in FLT3mut+ AML does not meet primary endpoint

FDA approves Xpovio for multiple myeloma after at least one prior therapy

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...